This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Proceedings of the National Academy of Sciences of the United States of America · 2024
Translational control of breast cancer plasticity.
Nature communications · 2020
Latest funding
- $120,000
The Integrated Stress Response as a Driver of Mitochondrial Fitness and a Therapeutic Vulnerability in KRAS-Mutant Lung Cancer
CIHR · 2025 · Supervisor
- $67,500
Does E-cigarette Use Enhance Lung Tumor Formation?
CIHR · 2025 · Co-investigator
- $1,032,750
Cracking the SOS Code: How eIF2B Fuels Mutant KRAS-Driven Cancer.
CIHR · 2025 · Nominated PI
2 publications.
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Cencic R, Im YK, Naineni SK, Moustafa-Kamal M, Jovanovic P, Sabourin V, Annis MG, Robert F, Schmeing TM, Koromilas A, Paquet M, Teodoro JG, Huang S, Siegel PM, Topisirovic I, Ursini-Siegel J, Pelletier J
Translational control of breast cancer plasticity.
Jewer M, Lee L, Leibovitch M, Zhang G, Liu J, Findlay SD, Vincent KM, Tandoc K, Dieters-Castator D, Quail DF, Dutta I, Coatham M, Xu Z, Puri A, Guan BJ, Hatzoglou M, Brumwell A, Uniacke J, Patsis C, Koromilas A, Schueler J, Siegers GM, Topisirovic I, Postovit LM
The Integrated Stress Response as a Driver of Mitochondrial Fitness and a Therapeutic Vulnerability in KRAS-Mutant Lung Cancer
Principal investigators: Zou, Jia Yi
Keywords: Chchd10; Combination Treatment; Integrated Stress Response; Kras Lung Cancer; Mitochondrial Dysfunction; Tumorigenesis
Does E-cigarette Use Enhance Lung Tumor Formation?
Principal investigators: Mann, Koren K
Keywords: Cancer
Cracking the SOS Code: How eIF2B Fuels Mutant KRAS-Driven Cancer.
Principal investigators: Koromilas, Antonis E
Keywords: Gene Expression; Guanine Exchange Factor; Kras Oncoprotein; Lung Adenocarcinoma; Raf-Mapk Pathway; Transgenic Mice; Translation Initiation Factor Eif2b; Tumor Progression
Deciphering the metabolic and tumorigenic functions of STAT1 in mutant KRAS cancer.
Principal investigators: Koromilas, Antonis E
Keywords: Anti-Tumor Drugs; Gene Expression; Kras Oncogene; Protein Phosphorylation; Sterol And Lipid Metabolism; Transcription Factor Stat1; Transgenic Mice; Tumor Formation
eIF2 phosphatase inhibitors in the treatment of Trastuzumab-resistant breast cancer.
Principal investigators: Koromilas, Antonis E
Keywords: Breast Cancer
The implication of the adaptive arm of the integrated stress response in KRAS lung cancer.
Principal investigators: Koromilas, Antonis E
Keywords: Hippo Pathway; Kras; Lung Cancer; Mitogen Activated Protein Kinases; Protein Phosphorylation; Signal Transduction; Transgenic Mice; Translation Initiation Factor Eif2
Molecular and Biological Determinants of the Integrated Stress Response.
Principal investigators: Koromilas, Antonis
Mechanisms and therapeutic implications of PKR and eIF2 phosphorylation in HER2 breast tumor suppression.
Principal investigators: Koromilas, Antonis E
Keywords: Breast Cancer; Chemotherapies; Eif2; Erk; Her2; Mrna Translation; Notch; Pkr; Transgenic Mice; Trastuzumab
The function of eIF2alpha phosphorylation in Ras signaling and lung tumorigenesis.
Principal investigators: Koromilas, Antonis E
Keywords: Cell Transformation; Chemotherapeutic Drugs; Mrna Translation; Protein Phosphorylation; Ras Oncoprotein; Transgenic Mice; Translation Factor Eif2
Elucidating the role of eIF2alpha phosphorylation pathway in ErbB2 mediated signalling and oncogenesis.
Principal investigators: Rahman, Mashrur
Keywords: Breast Cancer; Cell Lines; Cellular Signalling Pathways; Cellular Transfections; Drug Treatment; Immunoblotting; Molecular Biology; Mouse Model; Phosphoproteomics
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Biochemistry
- Molecular Oncology
- Lady Davis Institute for Medical Research
- Oncology
- Biomedical and Molecular Sciences
- Other
Co-authors at McGill University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Ivan Topisirovic
Lady Davis Institute for Medical Research
2 shared papers, latest 2024
Ivan Topisirovic
Faculty
2 shared papers, latest 2024
Jerry Pelletier
Biochemistry
1 shared papers, latest 2024
Lynne-Marie Postovit
Oncology
1 shared papers, latest 2020
Lynne-Marie Postovit
Biomedical and Molecular Sciences
1 shared papers, latest 2020
Sidong Huang
Biochemistry
1 shared papers, latest 2024
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.